SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-20-004274
Filing Date
2020-03-30
Accepted
2020-03-30 07:33:35
Documents
9
Period of Report
2020-03-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K oysterpoint-form8xkmar.htm 8-K 36697
2 EX-99.1 a2020-03x30xxoystxonse.htm EX-99.1 17369
3 EX-99.2 oysterpoint-8xkxriskfa.htm EX-99.2 497533
4 image01.jpg GRAPHIC 123
5 image011.jpg GRAPHIC 31484
6 image11.jpg GRAPHIC 123
7 image21.jpg GRAPHIC 123
8 image31.jpg GRAPHIC 123
9 image41.jpg GRAPHIC 123
  Complete submission text file 0001628280-20-004274.txt   597623
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 20754020
SIC: 2836 Biological Products, (No Diagnostic Substances)